We have located links that may give you full text access.
Alternative Rota-Flush Solution for Patients With Severe Coronary Artery Calcification who Undergo Rotational Atherectomy.
Journal of Invasive Cardiology 2017 January
We assessed the feasibility and safety of a rota-flush solution with 10,000 U of unfractionated heparin in 1 L of normal saline in patients who underwent rotational atherectomy.
BACKGROUND: Rotational atherectomy with the Rotablator (Boston Scientific) rotational atherectomy system is an effective way to modify severely calcified plaque. Potential complications include coronary spasm and slow-flow/no-flow. A pressured rota-flush solution is infused into the device to lubricate the drive shaft to minimize the risk of these complications as well as facilitate delivery of the device. RotaGlide lubricant (Boston Scientific), which decreases the friction between the drive shaft and RotaWire (Boston Scientific), is routinely added to the rota-flush solution. Antispasmotic agents including nitroglycerin and verapamil are commonly added to the rota-flush solution, but can lead to hemodynamic disturbances like hypotension and bradycardia.
METHODS: A total of 67 consecutive patients who underwent rotational atherectomy from July 2012 to June 2015 were included in this analysis. The primary endpoint was procedural success.
RESULTS: Procedural success was achieved in all patients. Significant hypotension occurred in 6%. No patients developed severe bradycardia requiring emergent insertion of a transvenous pacemaker. Major adverse cardiac and cerebral events occurred in 6.0%, all due to non-fatal myocardial infarction. Slow/no flow occurred in 7%, with subsequent resolution after intracoronary vasodilator therapy. Coronary spasm occurred in 4%. Stent thrombosis, perforation, flow-limiting dissection, and stent loss were not observed.
CONCLUSION: A rota-flush solution with 10,000 U of unfractionated heparin in 1 L of normal saline is a reasonable alternative to the routinely used solution which includes the RotaGlide lubricant, nitroglycerin, and verapamil.
BACKGROUND: Rotational atherectomy with the Rotablator (Boston Scientific) rotational atherectomy system is an effective way to modify severely calcified plaque. Potential complications include coronary spasm and slow-flow/no-flow. A pressured rota-flush solution is infused into the device to lubricate the drive shaft to minimize the risk of these complications as well as facilitate delivery of the device. RotaGlide lubricant (Boston Scientific), which decreases the friction between the drive shaft and RotaWire (Boston Scientific), is routinely added to the rota-flush solution. Antispasmotic agents including nitroglycerin and verapamil are commonly added to the rota-flush solution, but can lead to hemodynamic disturbances like hypotension and bradycardia.
METHODS: A total of 67 consecutive patients who underwent rotational atherectomy from July 2012 to June 2015 were included in this analysis. The primary endpoint was procedural success.
RESULTS: Procedural success was achieved in all patients. Significant hypotension occurred in 6%. No patients developed severe bradycardia requiring emergent insertion of a transvenous pacemaker. Major adverse cardiac and cerebral events occurred in 6.0%, all due to non-fatal myocardial infarction. Slow/no flow occurred in 7%, with subsequent resolution after intracoronary vasodilator therapy. Coronary spasm occurred in 4%. Stent thrombosis, perforation, flow-limiting dissection, and stent loss were not observed.
CONCLUSION: A rota-flush solution with 10,000 U of unfractionated heparin in 1 L of normal saline is a reasonable alternative to the routinely used solution which includes the RotaGlide lubricant, nitroglycerin, and verapamil.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app